Non-negligible Risk of Failure.

In its SmPC (summaries of product characteristics), Ranbaxy states that there is a non-negligible risk of medical abortion treatment failure, as follows: The non-negligible risk of failure, which occurs in 4.5 to 7.8% of the cases, makes the follow-up visit mandatory in order to check that abortion is complete.The patient should be informed that surgical... Continue Reading →

Create a website or blog at WordPress.com

Up ↑